Fc factOrs and Real-World hemophiliA Patient-ReporteD Outcomes
Stopped early
Conditions studied: Hemophilia A, Hemophilia B
In brief
The primary objective of the study is to evaluate the effectiveness of prophylactic treatment with recombinant Factor VIII Fc fusion protein (rFVIIIFc) and recombinant Factor IX Fc fusion protein (rFIXFc) therapy as assessed by patient treatment burden and health economic outcomes while maintaining disease control in males with hemophilia A or B.
Key facts
- Study ID
- NCT02392156
- Run by
- Bioverativ Therapeutics Inc.
- People needed
- 3
- Starts
- 2015-07-01
- Expected to finish
- 2015-12-01
- Last updated by the study team
- 2020-12-19
Who can join
Age: any. Sex: male. Healthy volunteers: not accepted.
Where it is running
- Research Site — Los Angeles, California, United States
- Research Site — East Lansing, Michigan, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.